Shots:
- Selecta to receive up front and ~$1.124B upon the achievement of development or commercial milestones or Takeda’s election continue its activities at specified development stages. Selecta is also eligible to receive royalties on future commercial sales
- The collaboration will utilize Selecta’s ImmTOR platform that accelerates transgene expression and addresses AAV vector immunogenicity to deliver transformative therapies for two indications
- ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of gene therapies, restore the body’s natural self-tolerance in autoimmune diseases & can induce tolerance to highly immunogenic proteins
Click here to read full press release/ article | Ref: Selecta | Image: Takeda
The post Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders first appeared on PharmaShots.
